Temsirolimus (CCI-779, Torisel) | 1600

mTOR inhibitor with anti-cancer activity. It has anti-angiogenic effects which may contribute to the antitumor activity of temsirolimus observed in breast cancer. Temsirolimus shows synergistic in vivo anti-myeloma effects in combination with dexamethasone in a xenograft model.

Temsirolimus (CCI-779, Torisel) is an mTOR inhibitor with anti-cancer activity. It has anti-angiogenic effects which may contribute to the antitumor activity of temsirolimus observed in breast cancer.

1600 | Temsirolimus (CCI-779, Torisel) DataSheet

Alternate Name/Synonyms: CCI-779,Torisel

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 162635-04-3

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₅₆H₈₇NO₁₆

Molecular Weight: 1030.29

Cell-Permeable?: Yes

Purity: ≥99%

Solubilities: DMSO (200 mg/ml)

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A mTOR inhibitor

MDL Number: MFCD00934421

PubChem CID: 6918289

SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O) C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC

InChi: InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7) 56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38 (6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10) 72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50, 58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+, 38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+, 56-/m1/s1

InChi Key: CBPNZQVSJQDFBE-FUXHJELOSA-N